14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Fri, 3 May 2024

Trading levels for OMER

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 3.66 7.65 %
R2 3.54 4.11 %
R1 3.47 1.92 %
Current price: 3.40
Support S1 3.22 -5.16 %
S2 3.15 -7.34 %
S3 3.03 -10.88 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 3.82 12.35 %
R2 3.68 8.24 %
R1 3.43 0.88 %
Current price 3.40
Support S1 3.19 -6.18%
S2 3.15 -7.35%
S3 3.05 -10.29%

OMER Predictions History

4 years ago
GoldenNugget predicted that OMER for 2019-05-07 is going $19.81 (1.08%)

4 years ago
NameNotImportant predicted that OMER for 2019-05-06 is going $19.28 (-1.73%)

4 years ago
GoldenNugget predicted that OMER for 2019-05-06 is going $18.99 (-3.19%)

5 years ago
GoldenNugget predicted that OMER for 2019-05-03 is going $19.51 (1.71%)

5 years ago
NameNotImportant predicted that OMER for 2019-04-29 is going $19.23 (2.23%)

5 years ago
NameNotImportant predicted that OMER for 2019-04-23 is going $19.05 (0.53%)

5 years ago
StockVader predicted that OMER for 2018-05-18 is going $21.19 (4.59%)

5 years ago
JS predicted that OMER for 2018-05-15 is going $21.92 (-10.31%)

5 years ago
marcos predicted that OMER for 2018-05-16 is going $26.13 (15.26%)

Rank:

6 years ago
Rollie predicted that OMER for 2017-06-28 is going $27.87 (24.03%)

Rank:
Click to get the best stock tips daily for free!

About Omeros Corporation

Omeros Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell tr... OMER Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT